Knesset committee demands inclusion of 'orphan disease' drug

"Orphan drug" is the first-ever treatment for Pompe disease, a rare but serious disease diagnosed in babies.

By
July 3, 2006 22:45
1 minute read.
myozyme 88

myozyme 88. (photo credit: )

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

A demand to include medications for rare "orphan" disorders such as Pompe's disease - which reportedly affects seven Israeli children - in the basket of health services was sounded by the Knesset Labor, Social Affairs and Health Committee on Monday. The committee, headed by Gil Pensioners Party MK Moshe Sharon, called on Health Minister Ya'acov Ben-Yizri to speed up registration of a drug called Myozyme, which was approved by the US Food and Drug Administration in April. This "orphan drug" is the first-ever treatment for Pompe disease, a rare but serious disease diagnosed in babies (its infantile form) or older people (late-onset) that drastically reduces their muscle and respiratory function. The drug could save the children's lives, the committee said. The committee discussion was initiated by MK Muhammad Barakeh, as some of the affected children are Arab and because of consanguinity (inbreeding or marriage of cousins). An enzyme called acid alpha-glucosidase, essential for normal muscle development, is missing or deficient in victims of Pompe disease, a inherited neuromuscular condition that often kills babies. Myozyme is given by intravenous infusion into a vein. Pompe disease is one of 40 genetic diseases known as lysosomal storage disorders and was first described in 1932 by Dutch physician J.C Pompe. who observed an infant with severe muscle weakness, an oversized tongue and a very enlarged heart but normal mental development. The Knesset committee also expressed its regrets that the ministry has done nothing to advance the treatment of "orphan" diseases by giving incentives, as in the US, to drug companies that research them and manufacturer drugs to treat them. Members called on Ben-Yizri to set criteria for defining such diseases in Israel and find a way to include relevant drugs in the basket of health services supplied by the health funds at nominal cost. Etti Semama, a Health Ministry representative, said at the meeting that Myozyme was presented for approval by the ministry's pharmaceutical registration department in June. The annual cost for treating a single child is 650,000 euros.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia

By UNIVERSITY OF MICHIGAN HEALTH SYSTEM